Dataset Information


The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.

ABSTRACT: Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD). However, less is known about the comparisons among different PPIs and their best dosage. We aimed to synthesize the available evidence through network meta-analysis to investigate the efficacy and safety of different PPIs in treating patients with NERD. Fifteen studies with 6309 patients were included in the meta-analyses. For the rate of symptomatic relief, compared with control groups, all interventions except rabeprazole 5?mg significantly increased rate of symptomatic relief. Among the comparisons of different interventions, omeprazole 20?mg group was associated with a higher rate of symptomatic relief in contrast to omeprazole 10?mg group (odds ratio, OR: 1.89, 95% confidence interval, CI: 1.34, 2.67; p-value: 0.0005) or rabeprazole 5?mg group (OR: 2.51, 95%CI: 1.16, 5.42; p-value: 0.019); dexlansoprazole 30?mg therapy significantly improved the rate of symptomatic relief compared with rabeprazole 5?mg group (OR: 2.64, 95%CI: 1.08, 6.43; p-value: 0.03). For the rate of adverse events, there was no significant difference among all interventions.


PROVIDER: S-EPMC5007473 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5626283 | BioStudies
2018-01-01 | S-EPMC6913203 | BioStudies
2018-01-01 | S-EPMC6330312 | BioStudies
1000-01-01 | S-EPMC6046475 | BioStudies
2010-01-01 | S-EPMC3352012 | BioStudies
2012-01-01 | S-EPMC3463177 | BioStudies
2019-01-01 | S-EPMC6647489 | BioStudies
2014-01-01 | S-EPMC4110066 | BioStudies
2020-01-01 | S-EPMC7500594 | BioStudies
2020-01-01 | S-EPMC7237708 | BioStudies